

(ATAC)], and occupancy by GATA1, TAL1, and CTCF in adult erythroblasts and BCL11A in HUDEP-2 cells. The genomic interval shown is chr11:5,109,001-5,305,000 in reverse orientation. (C) The intervals deleted in several alleles associated with HPFH or thalassemia (from the HbVar database) are shown as blue rectangles in register with the features shown in panel B; these are a subset of the deletions studied in Topfer et al. A browser session with the tracks shown in panels B and C allows further exploration and gives links to references and further information (https://main.genome-browser.bx.psu.edu/cgi-bin/hgTracks?hgS_doOtherUser=submit&hgS_otherUserName=ross&hgS_otherUserSessionName=BloodCommentary_Crossley and <http://usevision.org>). (D) A model for competition between the promoters for the adult *HBB* gene and the fetal *HBG* genes for activation by proximity to the LCR enhancer (blue lobes), encompassing chromatin interaction results from multiple sources.^{1,3,8} The diagram indicates the shift in promoter interactions with the LCR enhancer upon disruption of the *HBB* promoter. The brown disks on the 5' elements represent BCL11A, the gold gradient represents a zone of high transcriptional activity centered on the LCR, the light brown disk represents a repressive zone, and the gray line represents DNA.

<https://doi.org/10.1182/blood.2023020216>

© 2023 by The American Society of Hematology. Licensed under [Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International \(CC BY-NC-ND 4.0\)](https://creativecommons.org/licenses/by-nc-nd/4.0/), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Tong C, Zhang Y, Liu Y, et al. Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma. *Blood*. 2020;136(14):1632-1644.

Page 1643: In the correspondence paragraph under "Authorship," 2 of the 3 joint corresponding authors (Yao Wang and Zhiqiang Wu) are not listed. The corrected correspondence footnote is shown below.

Correspondence: Yao Wang, Chinese PLA General Hospital, No. 28 Fuxing Rd, Haidian District, Beijing 100853, China; e-mail: wangyao301@163.com; Zhiqiang Wu, Chinese PLA General Hospital, No. 28 Fuxing Rd, Haidian District, Beijing 100853, China; e-mail: wuzhiqiang1006@163.com; and Weidong Han, Chinese PLA General Hospital, No. 28 Fuxing Rd, Haidian District, Beijing 100853, China; e-mail: hanwdrsw69@yahoo.com.

<https://doi.org/10.1182/blood.2022017502>

© 2023 by The American Society of Hematology

Stein EM. IDH2 inhibition in AML. *Blood*. 2023;141(2):124-125.

In the conflict-of-interest disclosure on page 125, the following disclosure for Eytan M. Stein should have been included: "E.M.S. served on advisory boards for and received consulting fees from Bristol Myers Squibb, Celgene, and Agios Pharmaceuticals. Also, Memorial Sloan Kettering Cancer Center received research funds from those 3 companies."

<https://doi.org/10.1182/blood.2023020034>

© 2023 by The American Society of Hematology

Wang D, Sun Z, Zhu X, et al. GARP-mediated active TGF-β1 induces bone marrow NK cell dysfunction in AML patients with early relapse post-allo-HSCT. *Blood*. 2022;140(26):2788-2804.

On page 2788, the units in author affiliations 1 and 5 are in the wrong order. The byline and affiliations should read as follows:

Dongyao Wang,¹⁻⁴ Zimin Sun,^{1,4} Xiaoyu Zhu,^{1,4} Xiaohu Zheng,^{2,3} Yonggang Zhou,^{2,3} Yichen Lu,^{2,3} Peidong Yan,^{2,3,5} Huiru Wang,^{1,4} Huilan Liu,^{1,4} Jing Jin,^{2,3,5} Huaiping Zhu,⁴ Rui Sun,^{2,3} Yi Wang,^{2,3,5} Binqing Fu,^{2,3} Zhigang Tian,^{2,3} and Haiming Wei¹⁻⁴

¹Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, ²Institute of Immunology, School of Basic Medicine and Medical Center, ³The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medicine and Medical Center, ⁴Blood and Cell Therapy Institute, Anhui Provincial Key Laboratory of Blood Research and Applications, and ⁵Department of Hepatobiliary Surgery, Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China

<https://doi.org/10.1182/blood.2023020134>

© 2023 by The American Society of Hematology. Licensed under [Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International \(CC BY-NC-ND 4.0\)](https://creativecommons.org/licenses/by-nc-nd/4.0/), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.